Pharmacotherapy costs and medicines reimbursement policies of osteoporosis in the Republic of Bulgaria and Republic of North Macedonia
| Autor: | Rumyana Simeonova, Nikolay Danchev, Lidija Chakuleska |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
bisphosphonate
reimbursement status medicine.medical_specialty business.industry Osteoporosis Pharmaceutical Science Health Insurance Fund 030209 endocrinology & metabolism Pharmacy medicine.disease The Republic 03 medical and health sciences 0302 clinical medicine Pharmacotherapy bisphosphonate Health Insurance Fund reimbursement status Family medicine medicine Pharmacology (medical) 030212 general & internal medicine business Reimbursement |
| Zdroj: | Pharmacia 67(4): 199-207 |
| Popis: | The aim of the present study was to analyze and compare the number of health insured persons suffering from osteoporosis and antiosteoporotic drugs reimbursed by the National Health Insurance Funds (NHIF) in the Republic of Bulgaria (RBG) and Republic of North Macedonia (RNM) for the period 2015–2018. The reimbursement cost paid by the NHIF for the same period in both countries was surveyed. The results show an increase in both the number of patients with osteoporosis and the cost of the treatment. The most prescribed drug in R. Bulgaria is denosumab and it has the highest costs respectively, while in R.N. Macedonia the most prescribed and respectively the most expensive treatment is the bisphosphonate ibandronic acid, tablets of 150 mg. The trend of rising costs in both countries is likely to continue due to the increasing number of patients with osteoporosis. The number of patients and cost of pharmacotherapy in RNM and RBG are increasing but the reimbursement policy in RNM is more restrictive in terms of reimbursed medicines. On the other side, the RNM is with a higher level of reimbursement that might positively affect the cost of pharmacotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|